Terminated PHASE2 INTERVENTIONAL 1-arm NCT02020941

Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy

A Phase 2 Study of Carfilzomib and Bone Metabolism in Patients With Multiple Myeloma in First Relapse or Refractory to First Line Therapy

Sponsor: Attaya Suvannasankha

Conditions Refractory Multiple Myeloma

Interventions carfilzomib dexamethasone laboratory biomarker analysis

Updated 6 times since 2017 Last updated: Sep 14, 2016 Started: Sep 30, 2013 Primary completion: Jan 31, 2016 Completion: Apr 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow accrual

Other Refractory Multiple Myeloma trials with similar outcome

Browse all Refractory Multiple Myeloma trials

This PHASE2 trial investigates Refractory Multiple Myeloma and is currently terminated or withdrawn. Attaya Suvannasankha leads this study, which shows 6 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Sep 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Attaya Suvannasankha
National Cancer Institute (NCI)

Data source: Indiana University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Indianapolis, United States